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to Medicines
Reflexões sobre o Relatório do Secretário-Geral 
das Nações Unidas do Painel de Alto Nível em 
Acesso a Medicamentos
Frederick M. Abbott 1
I am honored to be asked by Dr. Jorge Bermudez to 
provide some additional commentary in reaction 
to his essay regarding the way forward following 
publication of the Report of the UN Secretary 
General’s High Level Panel on Access to Medicines 
(HLP). As a member of the Expert Advisory Group 
(EAG) to the HLP I had the opportunity to par-
ticipate in the meetings and dialogues in London, 
Johannesburg and New York, and had a number 
of opportunities to present my views. 
The Report is in many ways a milestone 
achievement. The HLP has called on governments, 
international organizations, the private sector, the 
science community and research institutions, and 
civil society to adopt new approaches to the way in 
which innovation and access are addressed. If the 
HLP’s call for action makes its way into General 
Assembly debate, and recommendations are more 
generally taken up taken up, this could be the be-
ginning of a transformation in the global approach 
to innovation and access. The recommendations 
are addressed, in any case, to a wide spectrum of 
stakeholders that may act independently of the 
General Assembly and its member states. Whether 
the Report has an enduring impact naturally will 
depend on what comes after, and that is what Dr. 
Bermudez addresses in his essay. However, even as 
a “standalone process”, the meetings and dialogues, 
in conjunction with the many submissions, un-
doubtedly advanced the progress of ideas.
Strong advocacy remains essential
As Dr. Bermudez has pointed out, the HLP 
Report fits within a series of developments at the 
international level directed toward promoting 
innovation in the pharmaceutical sector while 
emphasizing the importance of assuring access 
to the resulting treatments, preventives (such as 
vaccines) and diagnostics. There have been some 
very important successes, most notably the wide 
expansion of access to HIV-AIDS treatments 
brought about by sustained pressure from patient 
advocacy groups, supported by developing coun-
try governments (including that of Brazil), with 
substantial financing ultimately coming from the 
developed world. It is important to remember that 
progress on access to HIV-AIDS treatment is the 
result of a real political and economic struggle. 
Strong advocacy remains at the heart of achieving 
progress on access issues.
The HLP recommendations 
The HLP Report makes a number of important 
recommendations. Among these are insistence 
that governments refrain from exerting pressures 
against other governments in the course of trade 
negotiations, or in the course of the implemen-
tation of laws, to limit measures to promote and 
protect public health; that governments imple-
ment intellectual property laws, including patent 
laws, in a manner that guards against the grant of 
exclusive rights where not warranted by substantial 
inventive contribution; that governments make 
use of TRIPS Agreement flexibilities to promote 
access, including by taking advantage of “quick, 
fair, predictable and implementable” compulsory 
licensing; that new models of innovation delinking 
R&D costs from the price of medicines be pursued; 
that the results of publicly funded research be 
made widely available and accessible for use; that 
governments, multilateral organizations and pri-
vate sector companies must be more transparent 
and accountable for the way in which innovation 
and access is addressed, including through the 
provision of specific information regarding R&D 
costs and pricing, as well as clinical trial data and 
accessible patent status information.
The phenomenon of exerting pressure in trade 
negotiations to limit adoption and use of TRIPS 
flexibilities, and subsequent pressure in specific 
cases, started before the ink on the TRIPS Agree-
ment dried (i.e., more than 20 years ago). This 
is neither a secret nor a new development. But, 
identification of the practice by the UN Secretary 
General-appointed group, and a strong call for its 
end, should bolster the position of governments on 
the receiving end of pressure, and may give some 
pause to the demandeurs. It is an incremental step, 
but an important one.
Many of the submissions to the HLP were 
directed toward new models for innovation, 
including new mechanisms for financing. The 
HLP recognized that problems with respect to 
1 Florida State University College of Law.  fabbott@law.fsu.edu
the relationship between innovation and pricing 
are now of serious concern among high as well as 
lower income countries, and that solutions must 
be found. The Panel was somewhat cautious, 
however, regarding proposals for new models of 
innovation. The Report reflects concern that new 
models might “break” the existing patent/market 
exclusivity-based model without an adequate re-
placement, leaving the global community without 
funding for research. Discussion in the Report 
primarily focuses on antimicrobial resistance 
(AMR) and neglected diseases. I might have been 
more ambitious about new models because the 
existing system already is broken. I do not think 
the scientific community will abandon research on 
new treatments for disease because capital mar-
kets in New York and Hong Kong are dissatisfied 
with rates of return. Ways to fund research will be 
found since the demand for treatments, vaccines 
and diagnostics is not going away.
Each of the HLP recommendations reflects a 
history of policy and legal identification and advo-
cacy work. Notable is the demand for transparency 
with respect to drug R&D costs, which have been 
deliberately shrouded by the originator industry, 
forcing policy-makers to guess at the legitimacy of 
industry pricing practices. It is self-evident that the 
R&D costs of major originator companies are well-
known and identifiable within those companies. 
While it may be that predicting the success of any 
given R&D project is difficult depending on the 
nature of the project (e.g., harder with respect to 
basic research, easier with respect to incremental 
modification), the idea that major companies do 
not keep careful books and records that enable 
them to determine their actual R&D costs defies 
common sense.
An unfortunate reminder
I serve as Co-Chair of the Global Health Law 
Committee (GHLC) of the International Law 
Association. The GHLC made two submissions to 
the HLP on behalf of its members. One of these 
included proposal for establishing an essential 
medicines patent pool (EMPP) that would ini-
tially request voluntary licensing, and incorporate 
“effectively automatic” non-voluntary licensing 
should voluntary licenses not be forthcoming. 
Submission to the UN High Level Panel on Access 
to Medicines by the Global Health Law Committee 
of the International Law Association, Prepared by 
Ellen ‘t Hoen LLM, Prof dr Brigit Toebes, Katrina 
Perehudoff MSc, LLM, and Prof Frederick M 
Abbott, Feb. 22. 2016. The compulsory licensing 
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provision was proposed to be implemented im-
mediately, pending establishment of the EMPP 
system, with the systems thereafter integrated. 
For reasons that are not entirely clear, there was 
a view expressed by some members of the HLP that 
the proposal of “effectively automatic” compulsory 
licensing would somehow be inconsistent with the 
TRIPS Agreement, and in particular Article 31. Of 
course, Article 31(a) provides that “authorization 
of such use shall be considered on its individual 
merits”. As noted in our submission to the HLP, 
the Doha Declaration long ago confirmed that 
“Each Member has the right to grant compulsory 
licenses and the freedom to determine the grounds 
upon which such licenses are granted.” There is 
nothing in the TRIPS Agreement suggesting that 
a determination by public health authorities that a 
medicine is “essential” for the population, whether 
at the national or at the WHO level, cannot be used 
to determine the merits of granting an individual 
compulsory license. To the contrary, it is difficult 
to postulate a more compelling basis for such a 
determination. In processing the request for a 
compulsory license, the fact that a medicine has 
been determined to be essential can and should 
provide the grounds for an affirmative determina-
tion regarding the individual merits of that license.
There are other provisions of Article 31 that 
would be addressed in constructing an “effectively 
automatic” compulsory licensing mechanism for 
essential medicines. In our brief submission to 
the HLP, we observed that the refusal of a patent 
holder to grant a voluntary license on the terms 
established by the EMPP system would satisfy the 
requirement that the grantee had attempted to 
obtain a license on reasonable commercial terms 
and conditions. By way of illustration, Canada’s 
Access to Medicines Regime adopted to implement 
the WTO August 30, 2003 waiver for export under 
compulsory license uses a comparable mechanism. 
We noted, of course, that government use and 
emergency licenses do not in any case require an 
effort to secure a voluntary license.
The GHLC is not alone in having proposed a 
system for facilitating compulsory licenses for pat-
ented essential medicines. As a starting point for 
resolving tensions between international trade and 
IP rules, public health and human rights interests, 
this frankly appears a relatively straightforward 
and modest starting point. 
Ultimately, a “sizable minority” of the HLP 
would not agree to a proposal for effectively auto-
matic compulsory licensing of essential medicines, 
according to the Report, “because of concerns over 
the potential incompatibility of such measures 
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with the TRIPS Agreement and the unintended 
consequences that may result from such an ap-
proach. The High-Level Panel therefore did not 
reach consensus on this particular issue”.
The issue of potential “unintended conse-
quences” of several essential medicines-related 
proposals had been discussed at some length at 
the London Dialogue, including concern about 
potential strategic gaming (including lobbying) of 
essential medicines lists and the potential impact 
on investments in innovation. These concerns tie 
into broader issues regarding models of innova-
tion and access. I do not believe that these concerns 
justify impeding access to medicines that have 
been determined to be “essential”, though this does 
not mean these issues should not be addressed.
More concerning for present purposes is that a 
group of Panel members used unfounded concern 
regarding interpretation of the TRIPS agreement 
as the basis for rejecting a proposal to facilitate 
access to essential medicines. It is regrettable that 
the Report went off in this direction. Yet, even here 
there is an important lesson to be drawn from the 
process. Namely, despite high-minded pronounce-
ments that the TRIPS Agreement can and should 
be interpreted to promote access to medicines for 
all, the High Level Panel chartered by the UN Sec-
retary General to address in coherencies between 
public health, human rights, trade and intellectual 
property rules became hung up on a debate about a 
few words of the TRIPS Agreement -- a distraction 
from meaningful change. This proves the point of 
the UN Secretary General’s charter to the HLP: 
conflict between IP, trade rules, human rights and 
public health objectives remains to be resolved in 
a convincing manner. 
The way forward
As noted earlier, diverse stakeholders are ad-
dressed by the recommendations of the HLP, and 
these stakeholders should pursue the recommen-
dations in the Report. Beyond that, Governments 
must be persuaded to take up the Report and its 
recommendations in the UN General Assembly. 
It may be useful to promote adoption of a UN 
General Assembly Declaration embodying basic 
principles on access to medicines so as to embed 
the progressive ideas in the Report, and elsewhere 
in the submissions, into the body of international 
law. While such a Declaration might not have 
the immediate impact of creating a new funding 
mechanism, or in changing the terms of an al-
ready negotiated trade agreement, it might help 
persuade legislatures and judges to prioritize the 
right to health over narrow commercial interests, 
and it might provide the basis for longer-term 
systemic change.
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Commentary on Jorge Bermudez’s article
Comentário sobre o artigo de Jorge Bermudez
Mohga Kamal-Yanni 2
Thank you for inviting me to comment on the 
article by Dr. Jorge Bermudez, which provides a 
succinct overview of the debate on access to med-
icines as it progressed within the UN organiza-
tions and within the global trade system repre-
sented by the World Trade Organization (WTO). 
The overview focuses on the High Level Panel 
(HLP) and its report. My comment will centre on 
the HLP and the follow up needed for the world 
to benefit from its recommendations. 
Dr Bermudez rightly emphasized the impor-
tance of access to medicines as a human rights’ is-
sue and as a necessary pillar to achieve the SDGs. 
The HLP on health technologies was established 
by the UN Secretary General to “recommend 
solutions for remedying the policy incoherence 
between the justifiable rights of inventors, inter-
national human rights law, trade rules and pub-
lic health in the context of health technologies”. 
This aim carries a number of elements of critical 
importance to access to medicines. For a start, it 
does acknowledge the potential conflict o human 
rights and intellectual property (IP) rules- even 
though the US denies any such a conflict. 
The right to health is enshrined in UN decla-
rations and conventions since 19481. The Office 
of the UN High Commissioner on Human Rights 
clearly states that access to medicines is an enti-
tlement of the right to health2. On the other hand 
the right of the inventor is also recognized in the 
HLP mandate as well as in the human rights dec-
laration. However, the right of the inventor does 
not equate IP rules. Inventors can be rewarded in 
many ways including financial and non financial 
compensations. 
The aim of the HLP is carefully worded as 
“policy coherence” rather than achieving “bal-
ance”. In my view, it is wrong to “balance” the hu-
man right to health with the IP so-called “rights”. 
The human right to health, unlike IP “rights”, is 
acknowledged as a natural right. The HLP clearly 
states, “human rights are fundamental, universal 
entitlements that people inherently acquire by 
virtue of their birth”. “IP rights” are one policy 
tool among many for encouraging innovation 
and technological research and development 
(R&D)”3.
The HLP is an important step on the path to 
access to health technologies for a number of rea- 2 Oxfam GB. mkamalyanni@oxfam.org.uk
sons including its scope. Previous policy debates 
focused on R&D for neglected diseases and prices 
of medicines in developing countries. The HLP’ 
remit extends to all diseases and all health tech-
nologies in all countries. The price of medicines 
is recognized as a global problem. In reality, there 
is hardly a day that goes by without a media sto-
ry about the high prices of medicines, especially 
in the US, the country that heavily supports the 
monopoly of pharmaceutical companies, which 
leads to high prices. In Europe, where funding 
for health services is mainly through tax, health 
systems ration medicines or exclude expensive 
medicines from national reimbursement4. 
Dr Bermudez’s article also reminds us that 
access to medicines is one of the health targets 
of the Sustainable Development Goals (SDGs)5. 
In fact, the HLP’ published consultations, and 
especially its recommendations represent a seri-
ous step towards achieving the SDG health target 
through its strong recommendations to incentiv-
ize innovation and affordable prices6. 
On the innovation side, the HLP report em-
phasized proposals that have been already pro-
posed through the work of WHO and of civil 
society7,8. These include a strong focus on delink-
ing the cost (and hence the funding of R&D) 
from the price of the resulting products. This 
is a critical recommendation because the phar-
maceutical industry justifies the ever increasing 
prices of medicines by the high cost they incur 
in R&D. However, it is almost impossible to find 
out the real cost of R&D for medicines because 
of pharmaceutical companies’ secrecy. Therefore, 
the HLP report also strongly recommends trans-
parency on all aspects of R&D including on oth-
er costs that are normally included in the R&D 
package such as marketing. 
Deciding the global R&D agenda cannot be 
left to market incentives. The current system, 
based on IP monopoly, facilitates the highest pos-
sible profit to finance R&D, through the highest 
price that a market can bear. The HLP report rec-
ommends increasing public financing for R&D- 
a recommendation that both civil society and the 
WHO have been promoting for decades. How-
ever, increasing public financing alone will not 
produce affordable medicines without changing 
the monopoly of the pharmaceutical industry 
2444
K
am
al
-Y
an
n
i M
because the new funds will end up in the old sys-
tem producing the same high prices. Therefore, 
affordable prices must be a contractual obliga-
tion for all public financing programs. 
The HLP report proposed that the UN Sec-
retary General starts a process for UN member 
states to start negotiating an R&D agreement 
on coordination, financing and development of 
health technologies. The agreement needs to re-
sult in a binding convention that delinks the cost 
of R&D from the price of the end product in or-
der to promote access to health technologies for 
all. The latest UN declaration on antimicrobial 
resistance (AMR) signed by world leaders in Sep-
tember 2016, recommends delinking the cost of 
R&D of antimicrobial medicines from price and 
volume of the resulting products. We need to see 
how this is translated into affordable antimicro-
bial medicines, diagnostics and vaccines. 
On the access side, Dr Bermudez’s article 
elucidates that the HLP made important recom-
mendations, especially in emphasizing the im-
portance of the Doha Declaration which places 
public health before commercial interests. The 
HLP report also recognizes the huge political 
and economic pressures that countries face when 
governments try to use the Declaration to im-
plement measures such as compulsory licensing 
to decrease the price of highly priced medicines. 
The HLP report recommends that countries 
lodge at the WTO any pressure they face from 
other governments when they try to use the flex-
ibilities enshrined in the Trade Related Aspects 
on Intellectual Property Rights (TRIPS) agree-
ment. Unfortunately the HLP report was not 
bold enough to ban such pressure or to strong-
ly request the WTO to treat such pressure as a 
violation of the TRIPS agreement that requires 
punitive sanctions. 
The flourishing of Free Trade Agreements 
(FTAs) greatly limits governments’ ability to use 
the Doha declaration or any of the TRIPS flexi-
bilities. The HLP report gives clear examples of 
the limitations that are imposed on countries 
through the FTAs. The proposed Trans Pacific 
Partnership (TPP) is a prime example of FTAs, 
which ratchet up IP protection and enforcement. 
The HLP report acknowledges these TRIPS+ 
measures and their negative impact on public 
health and calls for governments to conduct an 
impact assessment before signing FTAs in order 
to evaluate potential impact of the measures in-
cluded in the agreement on public health. How-
ever, the Report falls short of condemning TRIPS 
+ and of recommending a ban on including IP 
in all bilateral and multilateral FTAs and treaties
Despite its shortcomings, the HLP report pro-
poses important recommendations to enhance 
access to health technologies. Yet the US govern-
ment and pharmaceutical companies have been 
attacking the HLP even before the report was 
published. There is a great concern that the work 
of the HLP could end up gathering dust on UN 
shelves. Concerted advocacy by relevant stake-
holders needs to be escalated in order to ensure 
the implementation of the report’s recommenda-
tions. 
The HIV story has taught us that political ac-
tions and real change require public campaigns 
and vigorous advocacy. Civil society organiza-
tions play an important role in advocacy for pro 
health global and national policies. Despite lack 
of financial and human resources, there has been 
a revival of the access to treatment movement 
that campaigned for access to HIV medicines. As 
the HLP report recommends, civil society organi-
zations need to be funded in order to fulfill their 
advocacy role for access to medicines. However, 
this advocacy cannot be left only to civil society. 
Members of the HLP and also the secretariat have 
to play their part in demanding political action. 
Yet the main actions must start from the UN 
itself. The UN Secretary General, who established 
the HLP in the first instance, needs to show his 
public support for the HLP report and to set up 
mechanisms to engage UN member states to 
commence implementation of its recommenda-
tions - for example starting to negotiate an R&D 
agreement. He should urge relevant UN bodies 
and other multilateral organizations such as the 
WTO to start implementing the recommenda-
tions relevant to their mandates.
Implementing the recommendations of the 
HLP report is the first litmus test of the world 
leaders’ serious commitments to the SDGs and 
their pledge to leaving no one behind. 
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Ensuring access; halting pressures!
Assegurando acesso; basta de pressões!
Claudia Vaca 3
Carolina Gómez 3
It is with great pleasure that we, people in the 
developing world working on global public 
health issues, receive the UN Secretary General´s 
High Level Panel Report on Access to Medicines 
(henceforth The Report). The importance of The 
Report relies perhaps not so much in its contents 
and recommendations, which of course are of the 
outmost relevance, but on the fact that it stems 
from the highest possible level at the UN System, 
as Dr. Bermudez pointed out on his article. 
Maybe it is not a coincidence that the concern 
for the lack of access to medicines gained such 
momentum when it became an issue for devel-
oped countries too. This is how Dr. Bermudez 
mentions it: “Additionally the issue of access to 
medicines and health technologies is no longer 
considered as a problem or threat restricted to 
low and middle-income countries, but is a prob-
lem that affects all human kind and also not re-
stricted to a group of diseases. We are no longer 
dealing with AIDS, TB and malaria or with the 
so-called Neglected Tropical Diseases, but with 
all diseases that affect human kind all over the 
world, including chronic non-communicable 
diseases.”
The debate sparkled by the price of Hepatitis 
C medicines, the ever-increasing price of already 
existing cancer medicines, the portrayal of some 
types of cancers almost like orphan diseases (i.e. 
market fragmentation) have started to put at risk 
the financial sustainability of all healthcare sys-
tems of the world, regardless of their level of de-
velopment. It is now evident, more than ever, that 
the paradigm for incentivizing health innovation 
is failing the rich and the poor of the world, even 
though the High Level Panel could not reach a 
consensus on this aspect. 
We in the developing world, wonder what 
needs to happen in order to reach such most 
needed consensus. The WHO Global Strategy 
and Plan of Action on Public Health, Innovation 
and Intellectual Property and the CEWG man-
aged to make it more or less politically correct 
to sustain that failure exists for developing coun-
tries, regarding their diseases (mainly tropical, 
communicable, infectious, neglected diseases). 
Between CEWG and The Report shocking things 
happened in the developed countries that would 3 Universidad Nacional de Colombia.  cpvacag@unal.edu.co
make all think that it is now accepted that the 
scope of the failure is wider: Sovaldi and its never-
seen-before-sky-rocket-price came into the mar-
ket and Spain, for instance, said that it could not 
pay for it for all patients that need it, sparkling a 
wave of social unrest and street demonstrations; 
hundreds of US Oncologists wrote an open letter 
warning about unpayable prices of cancer drugs; 
the English Cancer Drugs Fund (CDF) ran out of 
money. These are just some milestones that were 
not enough to make the panel reach consensus. 
Chikungunha, Zika and Ebola also happened in 
the meantime, and we cannot avoid wondering 
whether consensus would have been reached, 
had those epidemics affected more people living 
in the global north. 
It is sad, but there is hope. Change does not 
happen abruptly. Countries now need to push 
the UN Secretary General, WHO, all other rel-
evant UN agencies and the WTO to do some-
thing with The Report. A resolution accepting 
and adopting it must be passed and the UN must 
work to implement its recommendations and 
also to help countries implement them. We need 
to keep pushing, as we have done for about 20 
years since the “Revised Drug Strategy”; we have 
already come far, but not far enough. For a real 
change to happen, consensus needs to be reached 
on the failures of the current R&D system based 
on legal monopolies (patents, data exclusivity) as 
the main incentives for health innovation. De-
veloped countries, that foster the companies that 
have innovated, need to understand this.
As Dr. Bermudez correctly expresses it:
 In all forums, we have to state clearly that we 
cannot continue with a narrow scope of diseases or 
addressing only low and middle-income countries, 
but address all diseases and move the terminology 
from neglected diseases to neglected populations 
[...] If access to medicines is to be considered an 
essential human right, further than voluntary and 
compulsory licensing, the current IP system must 
be profoundly discussed and changed.
We could not agree more: something funda-
mental in the way we innovate needs to change. 
TRIPS flexibilities, especially compulsory li-
censes, are not the ideal solution the developing 
world bargained for when it agreed to TRIPS 
and to granting product patents for medicines. 
Flexibilities have failed to deliver. Their promise 
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as the way embedded in the intellectual property 
system (e.g. totally legitimate), to address public 
health needs, is generally void. The rationale is 
simple: compulsory licenses are an ad-hoc, case-
by-case solution to a structural, systemic prob-
lem. This should not be understood as a call for 
abandoning all attempts at compulsory licensing. 
On the contrary, they are all we have now, so we 
should embrace them, enable them, and make 
them easier to use, as The Report does.
But, to illustrate our point, let us examine 
more closely the case of Colombia, mentioned 
both on the Report and on Dr. Bermudez´ arti-
cle. In Colombia, the patent for imatinib was ini-
tially denied by the patent office in June of 2003. 
Novartis then took the patent office to court and 
won in February 2012, in part because the pat-
ent office did not litigate the case. During those 
almost 10 years, several generics entered the mar-
ket, but they had to exit once Novartis started en-
forcing its patent. Even though Novartis won the 
case in court in 2012, they just started enforcing 
their imatinib patent in 2014, right after the gov-
ernment had regulated, for the second time in the 
previous 3 years, the price of Glivec, reducing it 
in about 11%. Novartis claims that it took them 
that long to double check that their competitors 
were indeed infringing their patent (they bought 
samples and analyzed them in order to prove 
that the generic compound was the same as the 
patented one). Nonetheless, NGOs have affirmed 
that Novartis decision to enforce the patent is a 
reaction to governmental price setting. 
By 2014, 13 companies, including Novartis, 
held marketing authorizations for imatinib in 
Colombia. A difference of 198% was registerd 
between the average price per milligram for all 
imatinib generics (which ran between COP$50 
per mg. and COP$98 per mg.) and Glivec (sold 
at the time at COP$324 per mg.). Hence, the exit 
of all those competitors from the Colombian 
market and the sudden existence of a scenario 
of monopoly after so many years of competition, 
would have a considerable financial impact on 
the public health budget. It is worth mention-
ing at this point that in Colombia, imatinib was 
declared as an essential medicine in 2011 (years 
before WHO did) and it is fully covered by the 
public health insurance. 
In fact, at the beginning of the process, No-
vartis made the argument that there were no real 
access issues around imatinib because it was fully 
covered. This argument had worked years before, 
in the Kaletra case (the only other attempt for a 
Compulsory License in Colombia) and at that 
time, the Ministry of Health decided there were 
no merits for declaring Kaletra a medicine “of 
public interest” (a previous step required in Co-
lombia for a compulsory license) because, even 
though it was proven that the price was high 
compared to other countries, it was not being 
paid directly by patients. At the time, the Minis-
try of Health seemed to be saying “price does not 
matter, as long as the State can guarantee access”. 
But things have changed dramatically in Colom-
bia where price controls for medicines had been 
introduced. Nowadays no ministry of health in 
the world could take such a stand. Novartis, who 
has been represented by the same lawyer that rep-
resented Abbott when the Kaletra case took place 
in Colombia, quickly realized that that argument 
would not work, and replaced it with other ar-
guments. 
But lets not loose track of the story line. Giv-
en the eminent disappearance of competition 
and the extra financial burden for the healthcare 
system, on November 2014, civil society organi-
zations decided to trigger the process for the is-
suance of a compulsory license based on “public 
interest reasons”, which is just one of the many 
justifications allowed by the Colombian law for 
a compulsory license. In our country, the pro-
cess for this kind of compulsory licenses has 
two phases: one at the ministry of health, who 
declares that the health technology is “of public 
interest”; the second one at the patent office who 
issues the compulsory license and calculates the 
royalties. Nobody knows, because it has never 
happened (nor even tried out), whether the pat-
ent office can deny a compulsory license even 
though MOH declared the medicine to be “of 
public interest”.
Besides the juridical details and complexi-
ties of the case, the whole government, not just 
the Ministry of Health was subject to enormous 
amount of pressure by Novartis, Pharma, Swit-
zerland, the USA and others, as mentioned in The 
Report. Some of the letters pressuring Colombia 
were leaked and some of them are published in 
the MOH´s website (https://www.minsalud.gov.
co/salud/MT/Paginas/medicamentos-propie-
dad-intelectual.aspx). The Minister of Health 
also received enormous amount of support from 
civil society around the world: a letter signed by 
hundreds of academics and activists was sent to 
the President of Colombia. The US congress also 
got involved and a letter of support by a num-
ber of Congressmen, including Senator and at 
the time presidential candidate Bernard Sanders 
was received. In sum, in Colombia, as in India, 
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the Glivec case transcended our territory and be-
came a battlefield where titans clashed. 
The pressure resulted in the delaying of the 
decision and on division within the government. 
Almost a year and a half after the initial request 
was filed by civil society organizations, the Min-
ister of Health, on July 2016, declared that ima-
tinib was a medicine “of public interest”. None-
theless, there will be no compulsory license, just 
additional price controls. This decision is the 
result of tough negotiations between the min-
ister of trade and the patent office on the one 
hand, and the ministry of health on the other. 
The pressure and threats paid off. The trade sec-
tor of the government opposed the whole pro-
cess especially because in the meantime Novartis 
triggered the Investor- State Dispute Settlement 
Mechanism contained in the Bilateral Investment 
Treaty between Switzerland and Colombia. The 
Deputy Director of the Patent Office issued a for-
mal opinion, which was published by the Minis-
try of Health, arguing that in this case, given that 
there were no merits for a “declaration of public 
interest”, a compulsory license would amount 
to an expropriation. The Colombian Constitu-
tion declares that there shall be no expropriation 
without due compensation. Hence, he conclud-
ed, besides the royalty generics would have to pay 
Novartis, the State would have to compensate the 
company too. 
At least the Minister of Health was able to 
“save” the declaration of public interest, be-
cause the goal of Novartis was that not even that 
would take place. This was due, majorly, to the 
support by respected people and organizations 
of the world, including WHO, whose deputy 
director wrote a letter encouraging the Minis-
ter of Health and the UN high level panel, that 
decided to mention the case on The Reprt. The 
compromise reached between the sectors of the 
government was that the declaration would be 
issued, not for the purpose of a compulsory li-
cense, but for price controls that should be more 
stringent than the ones currently in place. The 
price for Glivec, it was agreed, should simulate 
competition. The Minister has announced that 
there would be additional price cuts for Glivec of 
about 40% to 45%. This has not happened yet. In 
Colombia, a commission is in charge of the con-
trol of prices of medicines. The minister of trade, 
the minister of health and an appointee by the 
president compose it. So the Minister had to take 
the battle to this new scenario. A few weeks ago, 
the commission issued, for public consultation, 
a draft methodology for the regulation of prices 
of medicines declared “of public interest” by the 
Ministry of Health. It is based on international 
reference pricing and the lowest price registered 
in countries where branded and generics are sold, 
will be the cap price in Colombia. The difference 
between this method and the already existing one 
is that this new one references prices of generics 
which the old one does not, and it sets the price 
at the lowest percentile, sets it at the 25th lowest 
percentile.
If this method is adopted, then it will be ap-
plied to Glivec. The good news is that it is a gen-
eral method, not an ad-hoc one just for Glivec. 
The other good news is that given that in spite of 
competition, Glivec still held 80% of the Colom-
bian imatinib market, the savings for the health 
care system might be grater than those obtained 
if the competitors remain in the market, because 
if a compulsory license was granted, they would 
have to raise the prices to cover the royalties due 
to Novartis.
Yet, this is still a speculation, because the new 
price for Glivec has not been set and no doubt 
Novartis will keep up the pressure. Civil Society 
organizations that triggered the whole process 
wonder whether this detour from a compulsory 
license towards mandatory governmental price 
controls was legal, because the norms that reg-
ulate the declaration of public interest explicitly 
say such declaration is done for the purpose of a 
compulsory license. Nonetheless, it seem a waste 
of resources to fight that legal battle given the ev-
ident lack of political will by the patent office, the 
ridiculous amount of time that litigation takes 
in Colombia but specially, given the fact that the 
patent will expire on June 2018. By the time some 
sort of result is envisaged, the patent, if not ex-
pired yet, will be so close to doing so, that it is 
expected that generic producer would rather wait 
for it to expire than pay royalties to Novartis.
Thousands of pages could be written telling 
all the details of this case. The point of writing 
these ones down was to illustrate the hardships a 
country must surmount to issue a compulsory li-
cense. All this energy, resources, time and political 
capital invested in just one medicine, is it worth 
it? From a public policy perspective, is it not pos-
sible to invest the same amount of resources aim-
ing at having a wider impact? Given the current 
R&D system, we are bound to these battles that 
are worth fighting but that seem pointless, when 
there are thousands of medicines all around that 
should be accessible to all. For example, paral-
lel to this enormous fight, the sells of nilotinib, 
a me-too of imatinib with a considerable higher 
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price, whose patent is also held by Novartis, have 
been rising consistently in Colombia while those 
of Glivec have lowered. Simply put: because the 
patent for Glivec has started to expire around the 
globe, Novartis has concentrated on promoting 
nilotinib, which is still under patent and will sus-
tain profits. This is proof of the distortions of our 
innovation model, and, we repeat along with Dr. 
Bermúdez, that unless something fundamental 
changes, countries are just not simply equipped 
to keep up just using compulsory licenses.
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Initially, I would like to acknowledge very much 
the efforts and the solid background of the com-
ments made by the eminent discussants on the 
original text “Contemporary challenges on Ac-
cess to Medicines: beyond the UNSG High-Level 
Panel”. 
Professor Frederick Abbott, the first discus-
sant, very clearly spells the relevance of the HLP 
Report as a milestone achievement, calling on all 
stakeholders to move forward, beyond the UN 
General Assembly. A series of developments ad-
dressing innovation and access within the phar-
maceutical sector have seen important successes, 
at the same time highlighting the relevance of 
developments supported by developing country 
governments.
Trade negotiations, pressures coming from 
developed countries to limit the adoption of 
TRIPS Flexibilities point to an immediate call for 
its end. Submissions received by the HLP are also 
mentioned seeking for new models for innova-
tion, considering the current system as already 
broken. The need to carefully weigh policy, legal 
and advocacy work to ensure feasibility is at the 
core of his comments.
The proposal for establishment of an essen-
tial medicines patent pool, incorporating volun-
tary licensing but at the same time ensuring in-
corporation of “effectively automatic” non-vol-
untary licensing is remarkably demystified with 
solid legal arguments and regretting that the HLP 
Report did not move further on exploring this 
absolutely feasible proposal, as well as arguing 
the need to discuss whereas a UN General As-
sembly Declaration would be a useful powerful 
tool in prioritizing human rights over individual 
commercial rights and pursuing a systemic lon-
ger-term change.
The second discussant, Dr. Mohga Ka-
mal-Yanni, from OXFAM UK initially agrees on 
the importance of addressing access to medicines 
as a human rights’ issue and a link to the achieve-
ment of the SDGs, acknowledging the conflict 
between human rights and IP as an individual 
right. Very sharply, Mohga states as wrong to try 
to balance human rights with IP as a right, as hu-
man rights must always prevail as natural rights. 
Talking about innovation, she highlights the HLP 
1 Escola Nacional de Saúde Pública, Fiocruz. 
jorge.bermudez@fiocruz.br
report on the work of WHO and civil society and 
stresses the need to delink cost and price within 
the pharmaceutical sector. Very correctively, we 
are remembered that market incentives are not 
adequate to decide the global R&D agenda and 
she supports a binding convention which the UN 
Secretary General is called to trigger a process for 
discussion, further than the recent UN declara-
tion recommending delinkage related to Antimi-
crobial Resistance (AMR).
Important recommendations are praised on 
the HLP report, acknowledging the negative im-
pact that TRIPS Plus provisions have on free trade 
agreements. Some shortcomings of the report are 
highlighted, including a stronger message requir-
ing the banning of pressures on IP provisions on 
bilateral or multilateral trade agreements.
Finally, the lessons learned with HIV are a 
message that we need strong advocacy and pub-
lic campaigns to ensure access as a human right, 
so a multiple stakeholder initiative must follow a 
strong push from the UN to really leave no one 
behind on achieving the SDGs.
The third discussants, Drs. Claudia Vaca and 
Carolina Gomez initially welcome the HLP Re-
port and its importance for the developing world, 
besides coming from the highest possible level at 
the UN System. At the same time, they reaffirm 
that the issues of access to medicines are no lon-
ger a restricted problem but affects all countries, 
regardless of their level of development and this 
has been a great change from previous discussion 
restricted to the WHO forums. Examples and 
milestones are correctly described by the discus-
sants, especially the most recent examples that 
have instigated this worldwide debate.
The discussants call for immediate changes 
on implementing the HLP recommendations 
and on discussing relevant issues elated to in-
novation, TRIPS Agreement, the failures on de-
liveries with TRIPS Flexibilities as not the ideal 
solution to address public health needs.
A great contribution to the debate by Drs. 
Vaca and Gomez is the indepth discussion on the 
recent case of Colombia, mentioned in the HLP 
and also in my article. The discussants share with 
us details of the process involving Novartis, ima-
tinib (Glivec) and generic versions and the diffi-
culties faced by the Colombian Government on 
attempting to publish a declaration of public in-
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terest by the Ministry of Health as an initial step 
on the possibility of issuing a compulsory license. 
This would be the first time of a case like this in 
Colombia, with great external pressures to halt 
this Government action.
Of special interest is being the discussion that 
the discussants bring to this debate, including the 
polemics intra-government and the “public in-
terest” as a step not necessarily toward compulso-
ry licensing but also aiming additional price con-
trols. I must highlight that a sign of alert is very 
clear from their comments and we need urgent 
further debate on the impact and implications 
of the triggering of the Investor-State Dispute 
Settlement Mechanism contained in bilateral in-
vestment agreements, which transfers the dispute 
from WTO to a distinct forum, allowing even 
companies to sue governments when they con-
sider that private trade interests are being ham-
pered with the issuing of governmental actions.
Anyway, the future is there to come, but the 
implementation of concrete consensual recom-
mendations, while at the same time, the debate 
of ideas and proposals comes high in the interna-
tional forums, must pave the way to the building 
of a more equitable and solidarity future and a 
better world for generations to come, leaving no 
one behind.
